NL2031176A - Radiopaque wire and occluder device with radiopaque function - Google Patents
Radiopaque wire and occluder device with radiopaque function Download PDFInfo
- Publication number
- NL2031176A NL2031176A NL2031176A NL2031176A NL2031176A NL 2031176 A NL2031176 A NL 2031176A NL 2031176 A NL2031176 A NL 2031176A NL 2031176 A NL2031176 A NL 2031176A NL 2031176 A NL2031176 A NL 2031176A
- Authority
- NL
- Netherlands
- Prior art keywords
- wire
- radiopaque
- nanoparticles
- double bond
- aqueous solution
- Prior art date
Links
- 239000000463 material Substances 0.000 claims abstract description 68
- 229920000642 polymer Polymers 0.000 claims abstract description 44
- 239000000017 hydrogel Substances 0.000 claims abstract description 34
- 239000002105 nanoparticle Substances 0.000 claims description 84
- 239000007864 aqueous solution Substances 0.000 claims description 58
- -1 polypropylene Polymers 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 52
- 239000002243 precursor Substances 0.000 claims description 50
- 125000000524 functional group Chemical group 0.000 claims description 40
- 239000004743 Polypropylene Substances 0.000 claims description 28
- 229920001155 polypropylene Polymers 0.000 claims description 28
- 239000003999 initiator Substances 0.000 claims description 25
- 238000000576 coating method Methods 0.000 claims description 21
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 20
- 239000000178 monomer Substances 0.000 claims description 20
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 20
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 18
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 18
- 239000000499 gel Substances 0.000 claims description 17
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 17
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 17
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 15
- 229920002674 hyaluronan Polymers 0.000 claims description 15
- 229960003160 hyaluronic acid Drugs 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 12
- 239000001263 FEMA 3042 Substances 0.000 claims description 12
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 12
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 12
- 229940033123 tannic acid Drugs 0.000 claims description 12
- 235000015523 tannic acid Nutrition 0.000 claims description 12
- 229920002258 tannic acid Polymers 0.000 claims description 12
- 229910052715 tantalum Inorganic materials 0.000 claims description 12
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 12
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 12
- 229910052721 tungsten Inorganic materials 0.000 claims description 12
- 239000010937 tungsten Substances 0.000 claims description 12
- 229910052797 bismuth Inorganic materials 0.000 claims description 11
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052737 gold Inorganic materials 0.000 claims description 10
- 239000010931 gold Substances 0.000 claims description 10
- 229910052741 iridium Inorganic materials 0.000 claims description 10
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052762 osmium Inorganic materials 0.000 claims description 10
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 10
- 229910052697 platinum Inorganic materials 0.000 claims description 10
- 229910052702 rhenium Inorganic materials 0.000 claims description 10
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 10
- 229910052703 rhodium Inorganic materials 0.000 claims description 10
- 239000010948 rhodium Substances 0.000 claims description 10
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 9
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 8
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical group CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- 229960003638 dopamine Drugs 0.000 claims description 8
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 8
- XHIRWEVPYCTARV-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide;hydrochloride Chemical compound Cl.CC(=C)C(=O)NCCCN XHIRWEVPYCTARV-UHFFFAOYSA-N 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 241001122767 Theaceae Species 0.000 claims description 7
- 125000004386 diacrylate group Chemical group 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 235000013824 polyphenols Nutrition 0.000 claims description 7
- 239000004952 Polyamide Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 229920002647 polyamide Polymers 0.000 claims description 6
- 238000005461 lubrication Methods 0.000 claims description 5
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 claims description 4
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940117986 sulfobetaine Drugs 0.000 claims description 4
- 238000003618 dip coating Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 238000010979 pH adjustment Methods 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 abstract description 16
- 238000011161 development Methods 0.000 abstract description 15
- 230000006378 damage Effects 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000012800 visualization Methods 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 230000018109 developmental process Effects 0.000 description 14
- 238000002791 soaking Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000008367 deionised water Substances 0.000 description 12
- 229910021641 deionized water Inorganic materials 0.000 description 12
- 238000009941 weaving Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000009832 plasma treatment Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000028831 congenital heart disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- 208000005422 Foreign-Body reaction Diseases 0.000 description 3
- XUBKPYAWPSXPDZ-UHFFFAOYSA-N [Ba].OS(O)(=O)=O Chemical compound [Ba].OS(O)(=O)=O XUBKPYAWPSXPDZ-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000005248 left atrial appendage Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035478 Interatrial communication Diseases 0.000 description 2
- 208000008883 Patent Foramen Ovale Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 208000013914 atrial heart septal defect Diseases 0.000 description 2
- 206010003664 atrial septal defect Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 208000003278 patent ductus arteriosus Diseases 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 150000003481 tantalum Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 2
- 201000003130 ventricular septal defect Diseases 0.000 description 2
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/129—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable or resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00526—Methods of manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00606—Implements H-shaped in cross-section, i.e. with occluders on both sides of the opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00623—Introducing or retrieving devices therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3966—Radiopaque markers visible in an X-ray image
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pathology (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a radiopaque wire and an occluder with radiopaque function. The radiopaque wire comprises a wire main body, a first and a second control end arranged on the 5 wire main body for picking and releasing the wire main body. The first and second control end are located at two ends of the wire main body. The radiopaque wire is a polymer wire with a lubricating layer on the surface; the lubricating layer carries a radiopaque material; or the radiopaque wire is a hydrogel wire carrying a radiopaque material. The radiopaque wire can be withdrawn in vitro after the occluder is released, avoiding permanent residue of 10 development marks inside the body, and eXpanding the scope of visualization, reducing the difficulty and risk of the operation. Having lower elastic modulus and lower frictional resistance, the end of the radiopaque wire will not cause damage to the tissue when withdrawn. 31
Description
FUNCTION Technical Field The disclosure relates to the field of medical equipment, in particular to a radiopaque wire and an occluder device with radiopaque function. Background Art Common congenital heart defects such as atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), patent foramen ovale (PFO) may cause heart function disorders and other cardiovascular and cerebrovascular complications. In addition, after atrial contraction decreases in patients with atrial fibrillation, the blood flow velocity in left atrial appendage connected to the left atrium will be further reduced, causing the blood to coagulate into thrombus. If thrombus breaks off, it is likely to reach the intracranial blood vessels through the bloodstream and block the small cerebral blood vessels, leading to ischemic stroke. The occluder can be implanted into the sites of total cardiac damage or the left atrial appendage by minimally invasive intervention. This method is the preferred treatment plan for patients with congenital heart disease due to its minor trauma, safe operation, and accurate short-term efficacy. At present, most of the framework of the minimally invastve interventional occluder used in clinical practice is of a mesh structure, which facilitates compression on the delivery device, so that the shape of occluder is restored and released at the diseased part after it is delivered into the body, thereby completing the occlusion function. In order to achieve this function, most of the previous minimally invasive interventional occluder frames are made of non-degradable nickel-titanium alloy. The non-degradable foreign body residues can cause complications such as valve damage, atrioventricular block, wear of cardiac tissue and thrombus etc. The risk of these complications affects the patient throughout his life. Using occluders made of degradable materials is an ideal choice to overcome these shortcomings. After implantation, it can induce regeneration of heart defect tissue, and completely disappear after heart repair, and will not adversely affect the patient's subsequent life. It is an ideal choice for the treatment for congenital heart defects and left atrial appendage occlusion. 1
However, compared with the traditional occluders made of nickel-titanium alloy materials, the current minimally invasive interventional degradable occluders cannot be visualized under X-rays, which is not convenient for doctors to transport and release the occluders. The prior art which adding a development mark on the occluder can solve this problem, but the development mark is generally a non-degradable metal, which will permanently remain in the body and cause foreign body reactions. In order to minimize the residual development mark, often only a small number of parts of the occluder is marked. And it is impossible to evaluate the overall releasing shape of the occluder, which increases the patient's surgical risk. Therefore, it is urgent to solve the technical problem that the developed mark remains in the body permanently and only a small number of parts of the occluder are marked.
Summary of the Disclosure Based on the above, the purpose of the present disclosure 15 to provide a radiopaque wire that can be withdrawn outside the body after the occluder is released, which can avoid the permanent residue of the development marks inside the body, and expand the scope of visualization at the same time, which is beneficial to reduce the difficulty and risk of the operation. And as it has lower elastic modulus and lower frictional resistance with good compliance, the end of the radiopaque wire will not cause damages to the tissue when tt is withdrawn.
The specific technical solutions are as follows: A radiopaque wire, comprising a wire main body and a first control end and a second control end arranged on the wire main body for picking and releasing the wire main body. Said first control end and second control end are respectively located at two ends of the wire main body; Wherein the material of the radiopaque wire is a polymer wire with a lubricating layer on the surface, and the lubricating layer carries a radiopaque material; or the radiopaque wire is a hydrogel wire carrying a radiopaque material.
In some embodiments, the polymer wire with a lubricating layer on the surface is prepared by the following steps: (1) loading a double bond polymerizable precursor on the surface of the polymer wire; 2
(2) coating the surface of the wire obtained in step (1) with a double bond polymerizable monomer and an initiator; (3) then solidifying the wire obtained in step (2); wherein, the radiopaque material is introduced in step (1) or step (2); the polymer wire is at least one from polypropylene wire, polytetrafluoroethylene wire and polyamide wire; the double bond polymerizable precursor is at least one from methacrylamide-based compounds, methacrylate-based compounds, acrylates, acrylamide-based compounds, acryloyl chloride, and methacrylic anhydride; the double bond polymerizable monomer is at least one from hyaluronic acid methacrylate, polyvinyl alcohol acrylate, polyethylene glycol diacrylate, vinyl pyrrolidone, sulfobetaine methacrylate and sulfonic acid acrylic acid.
In some embodiments, the methacrylamide-based compound is N-(3-aminopropyl) methacrylamide hydrochloride.
In some embodiments, the polymer wire with a lubricating layer and a radiopaque material on the surface is prepared by the following steps: (1) loading a double bond polymerizable precursor on the surface of the polymer wire; (2) immersing the wire obtained in step (1) into an aqueous solution containing a double bond polymerizable monomer and an initiator, and soaking for 5-15 minutes; (3) then solidifying the wire obtained in step (2); In some embodiments, the concentration of the double bond polymerizable monomer in said aqueous solution is 0.2 wt% to 50 wt%, and the concentration of the initiator is 0.05 wt% to 2 wt%. In some embodiments, in step (1), a double-bond polymerizable precursor is loaded on the surface of the polymer wire by method A or method B: Method A: under alkaline or neutral conditions, coating the surface of the polymer wire with crosslinkable functional group molecules, and then coating with the double bond polymerizable precursor, or mixing the crosslinkable functional group molecules with the double bond polymerizable precursor before coating; wherein, the crosslinkable functional group molecule is a tea polyphenol compound; preferably, the crosslinkable functional group molecule is at least one from tannic acid, epigallocatechin gallate and dopamine. 3
Method B: performing plasma treatment on the surface of the polymer wire, and then coating with a polymerizable double bond precursor. In some embodiments, method A is: immersing the polymer wire into an aqueous solution containing crosslinkable functional group molecules, adjusting the pH to 7-10, soaking for 4-8 hours, and taking out the wire. After cleaning, immersing the wire into an aqueous solution containing a polymerizable double bond precursor, soaking for 4 to 8 hours, then taking the wire out. In some embodiments, method B is: performing plasma treatment (introduction of hydroxyl groups) on the surface of the polymer wire, soaking in the ether solution of triethylamine, adding the double bond polymerizable precursor at 0-4°C, and reacting at room temperature for 20-30 hours, and then taking the wire out. In some embodiments, in method A, the concentration of the crosslinkable functional group molecule in the aqueous solution is 1-10 mg/mL; preferably 0.5-10 mg/mL. In some embodiments, in method B, the concentration of double bond polymerizable precursor in the aqueous solution is 5-15 v/v%. In some embodiments, the initiator is a photoinitiator, further the initiator is Irgacure
2959. In some embodiments, the solidification method in step (3) is light curing. In some embodiments, the aqueous solution of the double bond-containing polymerizable monomer and the initiator in step (2) may further include a crosslinking agent, which contains at least two polymerizable functional groups, such as polyethylene glycol diacrylate and N, N'-methylenebisacrylamide. In some embodiments, the radiopaque material is at least one from tungsten, tantalum, barium sulfate, bismuth, gold, platinum, osmium, rhenium, iridium, and rhodium; further, the radiopaque material is at least one from tungsten nanoparticles, tantalum nanoparticles, sulfuric acid barium nanoparticles, bismuth nanoparticles, gold nanoparticles, platinum nanoparticles, osmium nanoparticles, rhenium nanoparticles, iridium nanoparticles, and rhodium nanoparticles. In some embodiments, the base is sodium hydroxide or triethylamine. In some embodiments, the coating method is dip coating, wipe coating or spray coating. 4
In some embodiments, the hydrogel wire with a radiopaque material is prepared by the following steps:
(1) dispersing the radiopaque material in an aqueous solution of crosslinkable functional group molecules to obtain a radiopaque material modified by crosslinkable functional group molecules;
(2) then adding the radiopaque material obtained in step (1) into the gel precursor aqueous solution, and injecting it into a mold to solidify to obtain a hydrogel radiopaque wire;
wherein, the gel precursor is polyvinyl alcohol; the crosslinkable functional group molecule is a tea polyphenol compound, preferably, the crosslinkable functional group molecule is at least one from tannic acid, epigallocatechin gallate and dopamine.
In some embodiments, the concentration of crosslinkable functional group molecules in the aqueous solution in step (1) is 5-15 mg/mL.
In some embodiments, the concentration of the gel precursor in the gel precursor aqueous solution is 20-40 wt%. In some embodiments, the concentration of the radiopaque material in the gel precursor aqueous solution is 0.1-20 mg/mL.
In some embodiments, the pH of the aqueous solution of crosslinkable functional group molecules is 8-10. In some embodiments, the mold is a cylindrical mold.
In some embodiments, the diameter of the cylindrical mold is 0.1 to 0.3 mm.
In some embodiments, the solidification in step (2) is to repeat freezing and thawing over three times or more.
In some embodiments, the radiopaque material is at least one from tungsten, tantalum, barium sulfate, bismuth, gold, platinum, osmium, rhenium, iridium, and rhodium; further, the radiopaque material is at least one from tungsten nanoparticles, tantalum nanoparticles, sulfuric acid barium nanoparticles, bismuth nanoparticles, gold nanoparticles, platinum nanoparticles, osmium nanoparticles, rhenium nanoparticles, iridium nanoparticles, and rhodium nanoparticles.
Another object of the present disclosure is to provide an occluder with radiopaque 5 function, which comprises a supporting body and a radiopaque wire, which is any one of the above-mentioned radiopaque wires.
In some embodiments, the occluder includes a supporting body with a mesh structure and a first radiopaque wire, which is detachably arranged on the supporting body and includes a first control end, a second control end and a first radiopaque section. The first control end and the second control end are respectively located at two ends of the first radiopaque section. Said first radiopaque section is located in the supporting body. The supporting body is provided with a first end portion, and both the first and the second control ends protrude from the first end portion.
In some embodiments, said supporting body includes a first disc body, a second disc body and a connecting waist body. Said connecting waist body is located between the first disc body and the second disc body. Said first end portion is located on the first disc body. And said supporting body is further provided with a first piercing part, a second piercing part, a third piercing part, and a fourth piercing part. Said first piercing part is located between the first disc body and the connecting waist body. Said second piercing part is located between the second disc body and the connecting waist body. The third piercing part is symmetrically arranged with the first piercing part, and the fourth piercing part is symmetrically arranged with the second piercing part.
In some embodiments, the supporting body is further provided with a second end portion.
Said second end portion is located on the second disc body, and the second end portion is arranged corresponding to the first end portion.
In some embodiments, a second radiopaque wire is further included. The first radiopaque wire passes through the first end portion, the first piercing part, the second piercing part, the second end, the third piercing part and the four piercing parts, and is arranged on the supporting body and forms a first plane. Said second radiopaque wire is detachably arranged on the supporting body and forms a second plane, and the first plane and the second plane are set at a 90° angle.
In some embodiments, said second radiopaque wire includes a third control end, a fourth control end and a second radiopaque section. Said third control end and fourth control end are respectively located at two ends of the second radiopaque section. Both the third and the 6 fourth control ends protrude from the first end portion of the supporting body.
In some embodiments, the control end of the radiopaque wire is not its own end, but an additional control wire which is connected to any part of the main body of the radiopaque wire. One end of the control wire is connected to the main body of the radiopaque wire, and the other end extends from the occluder to outside of the body. Preferably, the control wire is connected to the midpoint part of the wire main body, and the movement of the radiopaque wire can be controlled by the control wire.
In some embodiments, a baffle film is further included. Said baffle film is sewn on the first disc body, the second disc body and the connecting waist body respectively. And said baffle film is provided with multiple layers.
In some embodiments, the material of the supporting body is a degradable material, including at least one selected from polylactic acid, polyglycolic acid, polycaprolactone, polyanhydride, and poly (p-dioxanone).
Compared with the prior art, the present disclosure has the following beneficial effects: The radiopaque wire provided by the present disclosure is detachably arranged on the supporting body with a mesh structure. The radiopaque wire is secured on the supporting body, therefore the occluder can be visible under X-ray during the process of putting the occluder into the human body, which enables the doctor to conveniently transport and release the occluder; and at the same time, the radiopaque section is located inside the supporting body to expand the imaging range, which is helpful to evaluate the release form of the occluder, and reduces the difficulty and risk of the operation. When the releasing of the occluder is completed, the radiopaque wire can be removed from the occluder and withdrawn from the human body by pulling the first control end or the second control end, so as to avoid the foreign body reaction and discomfort to the human body caused by the residual development marks inside the body.
At the same time, 1n the actual application process, the elastic modulus of the existing metal radiopaque wire is too high, and the material is hard, the compliance is poor, which makes it difficult for weaving and withdrawal, and the end may cause damages to the tissue during withdrawal. In order to solve the above technical problems, the present disclosure also developed a specific radiopaque wire material, which is a polymer wire with a lubricating 7 layer carrying a radiopaque material on the surface, or a hydrogel wire carrying a radiopaque material.
It has a lower modulus of elasticity, which is between 0.3-5G pa, while the modulus of elasticity of metal materials is more than 30 Gpa, therefore, said radiopaque wire will not cause damages to the tissue during the withdrawal process.
And the lubricating layer on surface of the radiopaque wire or the hydrogel wire is well lubricated, so the radiopaque wire has lower friction resistance, thereby it greatly reduces the resistance during the withdrawal process, and reduces possible accidental risks and related complications during the withdrawal process.
Brief Description of Drawings The drawings show specific embodiments of the technical solutions of the present disclosure and form as a part of the specification together with the specific implementations to explain the technical solutions, principles and effects of the present disclosure.
Unless otherwise specified or defined, in different drawings, the same reference numerals represent the same or similar technical features, and the same or similar technical features may also be represented by different reference numerals.
Fig. 1 is a schematic structural diagram of a supporting body according to an embodiment of the present disclosure.
Fig.2 is a schematic structural diagram of a radiopaque wire placed in a supporting body according to an embodiment of the present disclosure.
Fig. 3 is a schematic structural diagram of a control wire according to an embodiment of the present disclosure.
Description of reference signs: 10, supporting body; 11, first end portion; 12, second end portion; 13, first piercing part; 14, second piercing part; 15, third piercing part; 16, fourth piercing part; 20, first radiopaque wire; 21, first control end; 22, second control end; 23, first radiopaque section; 30, second radiopaque wire; 31, third control end; 32, fourth control end; 33, second radiopaque section; 50, control wire; 51, operation end.
Description of Embodiments In the following embodiments of the present disclosure, the experimental methods without specific conditions are usually in accordance with conventional conditions or in 8 accordance with the conditions recommended by the manufacturers. Various common chemical reagents used in the examples are all commercially available products.
Unless otherwise defined, all technical and scientific terms used in the present disclosure are the same as commonly understood by those skilled in the art. The terms used in the specification of the present disclosure are only for the purpose of describing specific embodiments, but not used to limit the present disclosure.
The terms “including” and “having” and any variations thereof in the present disclosure are intended to cover non-exclusive inclusions. For example, a process, method, device, product, or device which includes a series of steps is not limited to the listed steps or modules, but optionally includes steps that are not listed, or optionally other steps which are includes inherently in those processes, method, product, or equipment.
The “plurality” mentioned in the present disclosure means two or more. "And/or" describes the association relationship of the associated objects, indicating that there can be three types of relationships, for example, A and/or B, which can mean: A exists alone, A and B exist at the same time, and B exists alone. The character “/” generally indicates that the associated objects before and after are in an “or” relationship.
It should be noted that when a component is considered to be “secured” to another component, it can be directly secured to said another component, or it can be secured to said another component through a centered component; when a component is considered to be “connected” to another component, it can be directly connected to said another component, or be connected to said another component through a centered component at the same time; When an element is considered to be “installed on” another element, it can be directly installed on said another element, or be installed on said another element through a centered component at the same time; When an element is considered to “set on” another element, it can be directly set on said another element, or be set on said another component through a central element at the same time.
Unless specified or defined otherwise, the "said" and "the" used herein refer to the technical feature or technical content mentioned or described before the corresponding position, and the technical feature or technical content can be the same or similar as the mentioned technical feature or technical content.
9
There is no doubt that technical content or technical features that are contrary to the purpose of the present disclosure or obviously contradictory should be excluded.
As shown in Fig.1 and Fig.2, a radiopaque wire 20 is applied in the present disclosure, which comprises a wire main body, a first control end 21 and a second control end 22 arranged on the wire main body for picking and releasing the wire main body, and a first radiopaque section 23. Said first control end 21 and said second control end 22 are respectively located on the two ends of said first radiopaque section 23.
The material of said radiopaque wire is a polymer wire with a lubricating layer on the surface, and said lubricating layer carries a radiopaque material; or the radiopaque wire is a hydrogel wire carrying a radiopaque material.
Compared with the previous metal radiopaque wire, the radiopaque wire made of polymer wire or hydrogel wire has a lower elastic modulus, which is more conducive for the radiopaque wire to be weaved and secured on the occlude. At the same time, it avoids the possible damages to the tissue caused by the radiopaque wire during the withdrawal process due to the high elastic modulus, thereby helps to protect the human tissue. Preferably, said polymer wire with a lubricating layer on the surface is prepared by the following steps: (1) loading a double bond polymerizable precursor on the surface of the polymer wire; (2) coating the surface of the wire obtained in step (1) with a double bond polymerizable monomer and an initiator; (3) then solidifying the wire obtained in step (2); wherein, a radiopaque material is introduced in step (1) or step (2); The polymer wire is at least one from polypropylene wire, polytetrafluoroethylene wire and polyamide wire; the double bond polymerizable precursor is at least one from methacrylamide-based compounds, methacrylate-based compounds, acrylates, acrylamide-based compounds, acryloyl chloride, and methacrylic anhydride, preferably, the methacrylamide-based compound is N-(3-aminopropyl) methacrylamide hydrochloride; the double bond polymerizable monomer is at least one from hyaluronic acid methacrylate, polyvinyl alcohol acrylate, polyethylene glycol diacrylate, vinyl pyrrolidone, sulfobetaine methacrylate and sulfonic acid acrylic acid.
10
Wherein, the double bond polymerizable precursor is tightly loaded on the surface of the polymer wire to introduce double bonds without damaging the mechanical properties of the wire material; at the same time, the coated specific kind of double bond polymerizable monomer can form a cross-linked network with lubricating effect under the action of the initiator, to achieve good lubrication. The double bonds introduced on the polymer wire can further participate in the copolymerization of the double bond polymerizable monomer, enhancing the bonding force between the polymer wire and the cross-linked network with lubricating effect.
Further, said polymer wire loaded with radiopaque material and lubricating material on the surface is prepared by the following steps: (1) loading a double bond polymerizable precursor on the surface of the polymer wire; (2) immersing the wire obtained in step (1) into an aqueous solution containing a double bond polymerizable monomer and an initiator, and soaking for 5-15 minutes.
(3) then solidifying the wire obtained in step (2); Preferably, the concentration of the double bond polymerizable monomer in the aqueous solution is 0.2 wt% to 50 wt%, preferably 1-20 wt%, more preferably 5-15 wt%; and the concentration of the initiator is 0.05 wt% to 2 wt%, preferably 0.05 wt%~1 wt%, more preferably 0.05 wt%-0.5 wt%, further preferably 0.05 wt%~0.2 wt%.
Preferably, the initiator is a photoinitiator, further the initiator is Irgacure 2959; Preferably, the solidifying method in step (3) is light curing; Preferably, in step (1), a double-bond polymerizable precursor 1s loaded on the surface of the polymer wire by method A or method B: Method A: under alkaline or neutral conditions, coating the surface of the polymer wire with crosslinkable functional group molecules, and then coating with the double bond polymerizable precursor, or mixing the crosslinkable functional group molecules with the double bond polymerizable precursor before coating; wherein , the crosslinkable functional group molecule is a tea polyphenol compound, preferably, the tea polyphenol compound is at least one from tannic acid, epigallocatechin gallate and dopamine.
Method B: performing plasma treatment on the surface of the polymer wire, and coating with a polymerizable double bond precursor.
11
Wherein, method A is to coat the surface of the polymer wire with a specific type of cross-linkable photoenergy group molecules, then to coat with a double bond polymerizable precursor. The specific type of cross-linkable photo-energy group molecules have strong adhesion to the polymer wire, and can closely adhere to the surface of the polymer wire, thereby realizing the introduction of double bonds or radiopaque materials. Especially under alkaline conditions, the cross-linkable photoenergy group molecules can further undergo self-polymerization, so that they can better adhere to the polymer wire. At the same time, the specific type of crosslinkable photoenergy group molecule has an active reactive functional group, which can react with the double bond polymerizable precursor, and the two materials are connected through a covalent bond, which introduces a double bond, so as to tightly fix the double bond on the surface of the polymer wire.
Alternatively, the radiopaque material may be introduced in step (1) or step (2), or may be introduced simultaneously in step (1) or step (2). Further, when the radiopaque material is introduced in step (1), the radiopaque material can be mixed with the crosslinkable functional group molecules; when the radiopaque material is introduced in step (2), the radiopaque material can be mixed with an initiator.
Further, method A is: immersing the polymer wire into an aqueous solution containing crosslinkable functional group molecules, adjusting the pH to 7-10, soaking for 4-8 hours, and taking out the wire. After cleaning, immersing the wire into the aqueous solution containing the polymerizable double bond precursor, soaking for 4 to 8 hours, and taking out the wire; Optionally, performing plasma treatment on the polymer wire in method A, then immersing the treated wire into an aqueous solution containing cross-linkable functional groups molecules.
Further, method B is: performing plasma treatment (introduction of hydroxyl groups) on the surface of the polymer wire, then soaking the treated wire in the ether solution of triethylamine, adding the double bond polymerizable precursor at 0-4°C, and reacting at room temperature for 20-30 hours, taking out the wire.
Preferably, the concentration of the crosslinkable functional group molecule in said aqueous solution is 1-10 mg/mL; preferably 3-7 mg/mL ‚more preferably 4~6 mg/mL ‚further preferably 5 mg/mL; the concentration of double bond polymerizable precursor in the 12 aqueous solution is 0.5-10 mg/mL, preferably 0.5~5 mg/mL, more preferably 0.5~2 mg/mL, further preferably 0.8~1.5 mg/mL.
Preferably, said radiopaque material is at least one from tungsten, tantalum, barium sulfate, bismuth, gold, platinum, osmium, rhenium, iridium, and rhodium; further, the radiopaque material is at least one from tungsten nanoparticles, tantalum nanoparticles, sulfuric acid barium nanoparticles, bismuth nanoparticles, gold nanoparticles, platinum nanoparticles, osmium nanoparticles, rhenium nanoparticles, iridium nanoparticles, and rhodium nanoparticles.
Preferably, the base is at least one from sodium hydroxide and triethylamine.
Preferably, the coating method is dip coating, wipe coating or spray coating.
Preferably, the hydrogel wire carrying a radiopaque material is prepared by the following steps: (1) dispersing the radiopaque material in an aqueous solution of crosslinkable functional group molecules to obtain a radiopaque material modified by crosslinkable functional group molecules; (2) then adding the radiopaque material obtained in step (1) into a gel precursor aqueous solution, and injecting the mixture into a mold to solidify to obtain a hydrogel radiopaque wire; wherein, the gel precursor is polyvinyl alcohol; the crosslinkable functional group molecule is at least one from tannic acid, epigallocatechin gallate and dopamine.
Wherein, the radiopaque material has a better dispensability in the gel precursor aqueous solution after the radiopaque material is modified with crosslinkable functional group molecules. At the same time, the crosslinkable functional group molecules on the radiopaque material help to increase the hydrogen between the surface of the radiopaque material and the gel precursor, forming a cross-linked hydrogel network of the radiopaque material. Wherein, the introduction of the radiopaque material (especially the radiopaque nanoparticles) not only enables radiopaque function, but also further enhances the mechanical strength of the hydrogel radiopaque wire.
Preferably, the concentration of crosslinkable functional group molecules in the aqueous solution of crosslinkable functional group molecules and base in step (1) is 5-15 mg/mL, 13 more preferably 10 mg/mL. Preferably, the concentration of the gel precursor in the gel precursor aqueous solution is 20-40 wt%, more preferably 25~35 wt%, further preferably 30 wt %. Preferably, the concentration of the radiopaque material in the gel precursor aqueous solution is 5-20 mg/mL, more preferably 5-15 mg/mL, and more preferably 10 mg/mL. Preferably, the mold is a cylindrical mold, and the diameter of the cylindrical mold is 0.1 to 0.3 mm; more preferably 0.2 mm.
The present disclosure will be further described in detail with examples as below.
As shown in Fig.l and Fig.2, the embodiment further provides an occluder with radiopaque function, including a supporting body 10 and a radiopaque wire 20, and said radiopaque wire is any one of the above-mentioned radiopaque wires.
Specifically, the occluder includes a supporting body 10 with a mesh structure and a first radiopaque wire 20 which is detachably arranged on the supporting body 10, and the first radiopaque wire 20 includes a first control end 21, a second control end 22 and a first radiopaque section 23. Said first control end 21 and second control end 22 are respectively located at the two ends of the first radiopaque section 23. The first radiopaque section 23 is located inside the supporting body 10, the supporting body 10 is provided with a first end portion 11, and both the first control end 21 and the second control end 22 protrude from the first end portion 11.
By detachably arranging the radiopaque wire on the supporting body 10 with a mesh structure, the radiopaque wire can be secured on the supporting body 10 during the process of putting the occluder into the human body; therefore the occluder can be visible under X-ray, which enables the doctor to transport and release the occluder conveniently. At the same time, the radiopaque section is located inside the supporting body 10 to expand the imaging range.
Compared with the previous marking only a small part of the occluder, the entire radiopaque section is more conducive to evaluating the release form of the occluder, reducing the difficulty and risk of the operation; when the release of the occluder is completed, the radiopaque wire can be removed from the occluder and withdrawn from the human body by pulling the first control end 21 or the second control end 22, so as to avoid the foreign body reaction and discomfort to the human body caused by the residual development marks in the 14 body. Protruding the first control end 21 and the second control end 22 from the first end portion 11 of the supporting body 10 facilitates the pulling control of the radiopaque wire to be withdrawn from the human body, and preventing the radiopaque wire from falling off the occluder. It should be noted that the two control ends protrude from the supporting body 10 and extend outside of the body, which enables to conveniently perform the withdrawing operation of the radiopaque wire outside the body.
As shown in Fig. 1 and Fig. 2, said supporting body 10 includes a first disk body, a second disk body and a connecting waist body. Said connecting waist body is located between the first disk body and the second disk body and forms an "I"-shaped supporting body 10; said first end portion 11 1s located on the first disc body, and said supporting body 10 is further provided with a first piercing portion 13, a second piercing portion 14, a third piercing portion 15, a fourth piercing portion 16 and a second end portion 12. The first piercing portion 13 is located between the first disc body and the connecting waist body, the second piercing portion 14 is located between the second disc body and the connecting waist body. The third piercing portion 15 is symmetrically arranged with the first piercingportion 13 along the central axis of the supporting body 10, and the fourth piercing portion 16 is also symmetrically arranged with the second piercing portion 14 along the central axis of the supporting body 10. The second end portion 12 is located on the second disc body, and said second end portion 12 is arranged corresponding to the first end portion 11, wherein the first end portion 11 is the proximal end of the supporting body 10, and the second end portion 12 is the distal end of the supporting body 10. Since the position between the disc body and the connecting waist body is the position with the highest degree of bending deformation on the occluder, the piercing part is arranged between the disc body and the connecting waist body, so that the radiopaque wire can better match the contour of the supporting body 10 and improve the performance of the occluder. At the same time, by setting a plurality of piercing parts, the radiopaque wire is not easily loosen from the occluder during the process of sending the occluder into the human body, so as to ensure normal development and smooth insertion of the occluder. The following is an embodiment of the detachable arrangement of the first radiopaque wire 20 in the above-mentioned supporting body 10: The first radiopaque wire 20 starts from the mesh of the first end portion 11 of the 15 supporting body 10, extends toward the side close to the second end portion 12, firstly extending to the first piercing portion 13, and passing through the mesh of the first piercing portion 13; then extending to the second piercing part 14, and passing through the mesh of the second piercing part 14, and then extending to the second end part 12. After passing through the mesh of the second end portion 12, the first radiopaque wire 20 extends back toward the side close to the first end portion 11, and then extends to the third piercing portion 15. After passing through the mesh of the third piercing portion 15, the first radiopaque wire 20 extends to the fourth piercing portion 16, and finally passes through the mesh of the fourth piercing portion 16 and extends back to the first end portion 11 and protrudes from the first end portion
11. The first radiopaque wire 20 is detachably arranged on the supporting body 10 by the above-mentioned weaving method, which can expand the imaging range of the first radiopaque wire 20 in the occluder, and can roughly develop the outline of the entire occluder. Therefore, it solves the problem that the development marks are only located in individual parts of the occluder resulting in incomplete development, which is conducive to adjusting the release position of the occluder and grasping the release state of the occluder, reducing the difficulty of the doctor's operation and reducing the risk of the patient's operation. It should be noted that the above weaving method of the radiopaque wire is only one of the preferred embodiments, which can realize rapid weaving and development of the basic outline of the occlude. But according to the development requirements of the occluder, different piercing parts are positioned on the supporting body 10 to realize different weaving ways.
In order to further improve the radiopaque effect of the occluder, a second radiopaque wire 30 is added. The second radiopaque wire 30 includes a third control end 31, a fourth control end 32 and a second radiopaque section 33. The third control end 31 and the fourth control end 32 are respectively located at two ends of the second radiopaque section 33, and both the third control end 31 and the fourth control end 32 protrude from the first end portion 11 of the supporting body 10. The second radiopaque wire 30 has the same structure as the first radiopaque wire 20. The third control end 31 and the fourth control end 32 protrude from the first end portion 11 of the supporting body 10, which facilitates pulling and controlling the second radiopaque wire 30 to withdraw from the human body, and at the same time prevents the second radiopaque wire 30 from falling off the occluder. Likewise, it should be noted that 16 after protruding from the supporting body 10, the two control ends extend all the way to the outside of the body, so that the operation of withdrawing the radiopaque wire outside the body is more convenient.
The first radiopaque wire 20 is arranged on the supporting body 10 by the above-mentioned weaving method to form a first plane, and the second radiopaque wire 30 is weaved by the steps similar to the above-mentioned weaving method, so that said second radiopaque wire 30 is detachably arranged on the supporting body 10 to form a second plane. However, the difference from the above-mentioned weaving method is that the second plane formed by the weaving of the second radiopaque wire 30 forms an included angle of 90° with the first plane formed by the weaving of the first radiopaque wire 20. Since the occluder is a three-dimensional device, setting the second plane and the first plane at an angle of 90° can more comprehensively display the overall outline of the occluder, improve the development effect, and prevent the displacement of the occluder during implantation process from affecting the radiopaque angle of the first radiopaque wire 20. However, it should be noted that the number of radiopaque wires and the number of plane angles formed by weaving of the radiopaque wires can be adjusted according to the actual situation.
The above method of withdrawing the radiopaque wire from the human body by pulling the control end of the radiopaque wire 1s a preferred embodiment of the present disclosure. As shown in Fig. 3, in one of the embodiments, a separately control wire 50 is further included, which is arranged outside the supporting body 10. The control wire 50 is connected with the radiopaque wire at the position where the radiopaque wire is weaved at the second end portion 12 of the supporting body 10, and the end of the control wire 50 away from the connection with the radiopaque wire is the operation end 51, wherein, the operating end 51 extends outside the human body, and in order to prevent the control wire 50 from affecting the radiopaque wire to be smoothly weaved on the occluder, the control wire 50 can be connected with the radiopaque wire after the radiopaque wire is set. When the occluder is released, by pulling the operating end 51 of the control wire 50, both ends of the radiopaque wire 50 are pulled out from the second end portion 12 at the same time, which speeds up the removal of the radiopaque wire from the occluder and withdrawing from the human body, which improves work efficiency.
17
The material of said supporting body 10 is a degradable material, which is at least one from polylactic acid, polyglycolic acid, polycaprolactone, polyacid anhydride and poly (p-dioxanone). The occluder made of degradable materials can avoid complications such as valve damage, atrioventricular block, heart tissue wear, and thrombosis caused by the residual body, which is more conducive to the recovery of surgery and avoids adverse effects on the patient’s subsequent life.
The occluder is also provided with a baffle film (not shown in the figures), which is sewn on the first disc body, the second disc body and the connecting waist body respectively. The baffle film is provided with multiple layers. The baffle film can be prepared from degradable polymer materials such as polylactic acid. Sewing the baffle film on the occluder is beneficial to promote the growth of the endothelium, which makes the endothelium easier to crawl, and speeds up the recovery of the patient.
Source of material: Polyvinyl alcohol: Type 1799, weight average molecular weight 90,000.
Polyethylene glycol diacrylate: purchased from TCI, molecular weight 258. Example 1 Preparation of the occluder containing radiopaque wire A "I"-shaped occluder skeleton was woven with Paiy({1,4-tdioxan-2-one) wire, and then the radiopaque wire started from the proximal end of the occluder, and passed through the gap in the skeleton along the axial direction of the occluder to reach the distal apex of the occluder.
Then the radiopaque wire started to pass through the gap and returned to the proximal apex. The path of the radiopaque wire was symmetrically distributed along the central axis of the occluder, and finally the end of the radiopaque wire was exposed along the delivery system to in vitro. According to the similar steps, along the axial direction of the skeleton and in a direction of the 90° angle with the direction of the first radiopaque wire, a second radiopaque wire was weaved on the skeleton, and the end of said radiopaque wire was exposed along the conveying system to in vitro. During the implantation process of the occluder, since the radiopaque wire was located on the entire outline of the occluder skeleton, the entire occluder could be visualized, which solved the problem that the development marks are only located in individual parts of the occluder and the development is incomplete, facilitating to better adjust the release position of the occluder and grasp the release state of the occluder. At the same 18 time, the radiopaque wire on the occluder can be separated and withdrawn from the occluder by pulling the end outside the body, so as to avoid the residue of the radiopaque substance inside the body. Example 2. Polypropylene radiopaque wire coated with hydrogel (1) Preparation of hyaluronic acid methacrylate: Hyaluronic acid was dissolved in an aqueous solution (0.1 wt%), passed through a cation exchange resin, and then lyophilized. Then lyophilized hyaluronic acid was dissolved in DMSO solution, added with methacrylic anhydride equivalent to 0.2 equivalent (mass ratio) of hyaluronic acid, and reacted for 24 hours. Chloroform was added to the reaction solution for precipitation, and the precipitate was dissolved in water and dialyzed in a dialysis bag, and then hyaluronic acid methacrylate was obtained by lyophilization.
(2) The polypropylene wire was first soaked in a mixed aqueous solution of 5 mg/mL tannic acid and 1 mg/mL tungsten nanoparticles, and 1M sodium hydroxide was added to adjust the pH to 9. After soaking for 6 hours, the polypropylene wire was taken out and rinsed with deionized water for three times, then soaked in an aqueous solution (1 mg/mL) of N-(3-aminopropyl) methacrylamide hydrochloride (pH=8) for 6 hours. The polypropylene wire was taken out and rinsed with deionized water for three times to obtain a polypropylene wire with surface-modified by double bonds and radiopaque nanoparticles.
In this step, double bonds and radiopaque nanoparticles could be introduced simultaneously on the surface of various wires through simple steps without damaging the mechanical properties of the wire body. Wherein, the radiopaque nanoparticles have a larger surface area, which can further increase the introduction of double bonds, and at the same time radiopaque function can be realized. Moreover, the method does not require pretreatment to the wire.
(3) The polypropylene wire with surface-modified by double bonds and radiopaque nanoparticles obtained in step (2) was soaked in an aqueous solution of 0.5 wt% hyaluronic acid methacrylate and 0.1 wt% Irgacure 2959 as a photoinitiator for 10 minutes, then was taken out for solidifying under ultraviolet light. The hyaluronic acid methacrylate in this step can form a cross-linked network by itself under the 19 polymerization of the initiator, and thereby playing a lubricating role. The double bond on the surface of the polypropylene wire can simultaneously participate in the copolymerization of the double bond in the hyaluronic acid methacrylate, and thereby enhancing the bonding force between the hyaluronic acid network and the polypropylene wire. Example 3. Polypropylene radiopaque wire coated with hydrogel (1) Preparation of polyvinyl alcohol acrylate: 5.0 g of polyvinyl alcohol (PVA) was dissolved in 100 mL of dimethyl sulfoxide (DMSO). Dimethylaminopyridine and glycidyl acrylate were added with final concentration of 1.0 mol % (relative to the hydroxyl groups of PVA) and 0.025 mol % (relative to the hydroxyl groups of PVA), respectively. After stirring at 60 °C for 6 hours, the reaction solution was added with acetone for precipitation. The precipitate was vacuum-dried for 2 days and stored at —5 °C in the dark.
(2) Firstly, the polypropylene wire was soaked in a mixed aqueous solution of 5 mg/mL tannic acid and 1 mg/mL tantalum nanoparticles, and 1 M sodium hydroxide was added to adjust the pH to 9. After soaking for 6 hours, the polypropylene wire was taken out and rinsed for three times with deionized water, then soaked in an aqueous solution (1 mg/mL) of N-(3-aminopropyl) methacrylamide hydrochloride (pH=8) for 6 hours. The polypropylene wire was taken out and rinsed with deionized water for three times to obtain a polypropylene wire with surface-modified by double bonds and radiopaque nanoparticles. In this step, double bonds and radiopaque nanoparticles can be introduced simultaneously on the surface of polypropylene wire through simple steps without damaging the mechanical properties of the wire body. The radiopaque nanoparticles can further increase the introduction of double bonds, and at the same time, radiopaque function can be realized. Moreover, the method does not require pretreatment to the wire. (3) The polypropylene wire with surface-modified by double bonds and radiopaque nanoparticles obtained in step (2) was soaked in an aqueous solution of 1 wt% polyvinyl alcohol acrylate and 0.1 wt% Irgacure 2959 as a photoinitiator for 10 minutes, then was taken out for solidifying under ultraviolet light. The polyvinyl alcohol acrylate in this step 20 can form a cross-linked network by itself under the polymerization of the initiator, and thereby playing a lubricating role.
The double bond on the surface of the polypropylene wire can simultaneously participate in the copolymerization of the double bond in the polyvinyl alcohol acrylate, and thereby enhancing the bonding force between the hyaluronic acid network and the polypropylene wire.
Example 4. PTFE-radiopaque wire coated with polymer (1) The polytetrafluoroethylene (PTFE) wire was soaked in an aqueous solution of 5 mg/mL epigallocatechin gallate and 1 mg/mL barium sulfate nanoparticles, and then 1 M sodium hydroxide was added to adjust the pH to 9. After soaking for 6 hours, the polypropylene wire was taken out and rinsed with deionized water for three times, then soaked in N-(3-aminopropyl) methacrylamide hydrochloride aqueous solution (1 mg/mL) (pH=8) for 6 hours.
The tetrafluoroethylene wire was taken out and rinsed with deionized water for three times to obtain a polytetrafluoroethylene wire with surface-modified by double bonds and radiopaque nanoparticles.
In this step, double bonds and radiopaque nanoparticles can be simultaneously introduced on the surface of the polytetrafluoroethylene wire through a simple step without causing damage to the mechanical properties of the wire body. (2) The polytetrafluoroethylene wire with surface-modified by double bonds and radiopaque nanoparticles obtained in step (1) was soaked in aqueous solution of 10 wt% vinylpyrrolidone and 0.1 wt% Irgacure 2959 as a photoinitiator for 10 minutes, then was taken out for solidifying under ultraviolet light.
The vinylpyrrolidone monomer in this step can be polymerized under the action of the initiator to form polyvinylpyrrolidone by itself, which has good hydrophilicity and lubricity.
At the same time, the double bonds on the surface of the wire also participated in the polymerization of vinylpyrrolidone, which enhanced the binding force with the substrate; and the double bond epigallocatechin gallate of the lower layer of the polyvinylpyrrolidone also produced hydrogen bonding, which further enhanced the binding force with the substrate.
Hydrogen bonding was generated between polyvinylpyrrolidone and the underlying double bond gallocatechin gallate, which further enhanced the binding force with the substrate. 21
Example 5. PTFE-radiopaque wire coated with polymer (1) The polytetrafluoroethylene (PTFE) wire was soaked in an aqueous solution of 5 mg/mL dopamine and 1 mg/mL barium sulfate nanoparticles, and then 1 M sodium hydroxide was added to adjust the pH to 8.5. After soaking for 6 hours, the polypropylene wire was taken out and rinsed with deionized water for three times, then soaked in N-(3-aminopropyl) methacrylamide hydrochloride aqueous solution (1 mg/mL) (pH=8) for 6 hours.
The tetrafluoroethylene wire was taken out and rinsed with deionized water for three times to obtain a polytetrafluoroethylene wire with surface-modified by double bonds and radiopaque nanoparticles.
In this step, double bonds and radiopaque nanoparticles can be simultaneously introduced on the surface of the polytetrafluoroethylene wire through a simple step without causing damage to the mechanical properties of the wire body. (2) The polytetrafluoroethylene wire with surface-modified by double bonds and radiopaque nanoparticles obtained in step (1) was soaked in aqueous solution of 10 wt% vinylpyrrolidone and 0.1 wt% Irgacure 2959 as a photoinitiator for 10 minutes, then was taken out for solidifying under ultraviolet light.
In this step the sulfobetaine methacrylate monomer can be polymerized under the action of an initiator to form a zwitterionic hydrogel, which has good hydrophilicity, lubricity and anticoagulant properties.
The double bonds on the surface of the wire also participated in the polymerization of the hydrogel, which enhanced the bonding force between the hydrogel and the substrate.
Example 6. PTFE-radiopaque wire coated with hydrogel (1) Firstly, plasma surface treatment was performed to the PTFE wire, then soaked the wire in an aqueous solution of 5 mg/mL dopamine and 1 mg/mL barium sulfate nanoparticles, and IM sodium hydroxide was added to adjust the pH to 8.5. After soaking for 6 hours, and the polypropylene wire was taken out and rinsed for three times with deionized water, and then was soaked in N-(3-aminopropyl) methacrylamide hydrochloride aqueous solution (1 mg/mL) (pH=8) for 6 hours.
The polytetrafluoroethylene wire was taken out and rinsed for three times with deionized water.
In this step, double bonds and radiopaque 22 nanoparticles can be introduced simultaneously on the surface of the polytetrafluoroethylene wire without damaging the mechanical properties of the wire body. (2) The polytetrafluoroethylene wire obtained in step (1) was soaked for 10 minutes in an aqueous solution of 10 wt% sulfonic acid acrylic acid and 0.5 wt% polyethylene glycol diacrylate and 0.1 wt% Irgacure 2959 as a photoinitiator, then was taken out for solidifying under ultraviolet light. In this step, the sulfonic acid acrylic monomer and polyethylene glycol diacrylate can be polymerized under the action of the initiator to form an anionic hydrogel, which has good hydrophilicity, lubricity and anticoagulant properties.
The double bonds on the surface of the material also participated in the polymerization of the hydrogel, which enhanced the bonding force between the hydrogel and the substrate.
Example 7. Polyamide radiopaque wire coated with hydrogel (1) Firstly, plasma treatment was performed on the surface of the polyamide wire to introduce hydroxyl groups, then soaked the wire in an ether solution containing 8wt%o triethylamine, and added with 10% volume fraction of acryloyl chloride at 0°C. After reacted at room temperature for 24 hours, the polypropylene wire was taken out and rinsed for three times with deionized water. In this step double bonds can be introduced on the surface of the polyamide through simple steps.
(2) The polypropylene wire with surface-modified by double bonds and radiopaque nanoparticles obtained in step (1) was soaked in 1 wt% hyaluronic acid methacrylate aqueous solution, 1 mg/mL bismuth nanoparticle aqueous solution and 0.1 wt % Irgacure 2959 as a photoinitiator for 10 minutes , and then was taken out for solidifying under ultraviolet light. In this step, the hyaluronic acid methacrylate can be polymerized under the action of an initiator to form a hydrogel. At the same time, the radiopaque nanoparticles were encapsulated in the hydrogel, which enabled good lubricity and radiopaque performance. The double bonds on the surface also participated in the polymerization of the hydrogel, which enhanced the bonding force between the hydrogel and the substrate.
23
Example 8. Hydrogel radiopaque wire
0.01 g of tantalum nanoparticles were ultrasonically dispersed in 10 mL of 10 mg/mL tannic acid aqueous solution, and sodium hydroxide solution was added to adjust the pH to 9. After 6 hours of reaction, the solution was centrifuged to obtain tannic acid-modified tantalum nanoparticles. The obtained tannic acid-modified tantalum nanoparticles were added to a 30 wt% polyvinyl alcohol aqueous solution for dispersion, with a final concentration of 10 mg/mL, and the obtained solution was injected into a cylindrical mold with a diameter of 0.2 mm, and frozen at -20°C for 24 hours. Then it was taken out for melting, and repeated freeze-thaw for three times to obtain a nanoparticle-enhanced hydrogel radiopaque wire. The nanoparticles of the radiopaque wire obtained by this technology, are surface-modified by tannic acid, so they have better dispersibility in the polyvinyl alcohol solution. The tannic acid on the nanoparticles helps to increase the hydrogenation of the nanoparticles in the polyvinyl alcohol to form a cross-linked hydrogel network of nanoparticles, in which the introduction of nanoparticles not only has radiopaque function, but also further enhances the mechanical strength of the hydrogel radiopaque wire. Comparative Example 1 A radiopaque wire, the preparation of which is as follows: the polypropylene wire was soaked in a mixed aqueous solution of 5 mg/mL tannic acid and 1 mg/mL tungsten nanoparticles; and then 1 M sodium hydroxide was added to adjust the pH to 9. After soaking for 6 hours, the polypropylene wire was taken out and rinsed for three times with deionized water. Comparative Example 2 A radiopaque wire, which is a polypropylene wire without treatment. Comparative Example 3 A radiopaque wire, which is a nickel-titanium alloy wire with a diameter of 0.2 mm. Test of withdrawing ability and elastic modulus 24
The radiopaque wires of Examples 2-8 and Comparative Examples 1-3 were weaved on the same occluder by the method described in Example 1. After the occluder was conveyed and released, one end of the radiopaque wire was secured by a tension machine, and the radiopaque wire was withdrawn to test its withdrawal force. From the results in Table 1 as below, the radiopaque wires of examples 2-8 of the present disclosure have lower withdrawal force and lower elastic modulus. The coating on the surface of the polymer wires has no obvious influence on the modulus of the polymer wires, and the withdrawal force of the radiopaque wire is significantly reduced after the surface is polymerized with monomers.
Table 1 The various technical features in the above-described embodiments can be combined in various ways. In order to provide a concise description, the above-described embodiments do not describe all the possible combinations of the technical features . However, those combinations which are not described should be within the scope of the description as long as no contradiction occurs in the combinations of these technical features.
The above-described embodiments represent only several embodiments of the present disclosure, which are described in specific detail but should not be construed as limitations on the scope of the claims. It should be noted that modifications and improvements can be made by those skilled in the art without departing from the spirit of the disclosure, all of which fall within the scope of the present disclosure.
Accordingly, the scope of the present disclosure should be subject to the appended claims. 26
Claims (14)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110335915.8A CN113081312B (en) | 2021-03-29 | 2021-03-29 | Developing wire and plugging device with developing function |
Publications (2)
Publication Number | Publication Date |
---|---|
NL2031176A true NL2031176A (en) | 2022-07-20 |
NL2031176B1 NL2031176B1 (en) | 2024-05-06 |
Family
ID=76670660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2031176A NL2031176B1 (en) | 2021-03-29 | 2022-03-07 | Radiopaque wire and occluder device with radiopaque function |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN113081312B (en) |
NL (1) | NL2031176B1 (en) |
WO (1) | WO2022206148A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113081312B (en) * | 2021-03-29 | 2022-04-15 | 四川大学 | Developing wire and plugging device with developing function |
CN116919652B (en) * | 2023-09-18 | 2024-01-19 | 北京心祐医疗科技有限公司 | Degradable filter |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10342546B2 (en) * | 2013-01-14 | 2019-07-09 | Microvention, Inc. | Occlusive device |
CN103110444A (en) * | 2013-01-22 | 2013-05-22 | 陈平根 | Biodegradable fabric body capable of being developed and conveying device |
WO2015153996A1 (en) * | 2014-04-03 | 2015-10-08 | Micro Vention, Inc. | Embolic devices |
CN205359523U (en) * | 2015-12-08 | 2016-07-06 | 上海形状记忆合金材料有限公司 | Directional atrial septal defect plugging device |
CN110313946A (en) * | 2018-03-28 | 2019-10-11 | 上海微创医疗器械(集团)有限公司 | A kind of plugging device and preparation method thereof |
US11672541B2 (en) * | 2018-06-08 | 2023-06-13 | Boston Scientific Scimed, Inc. | Medical device with occlusive member |
CN109529128B (en) * | 2018-11-30 | 2021-12-14 | 中国科学院长春应用化学研究所 | Anti-infection coating and preparation method thereof |
CN109692027A (en) * | 2018-12-03 | 2019-04-30 | 北京泰杰伟业科技有限公司 | A kind of whole course visible takes thrombus device |
CN211934176U (en) * | 2019-12-31 | 2020-11-17 | 杭州诺芮医疗科技有限公司 | Improve left auricle of heart and melt plugging device of security |
CN212415821U (en) * | 2020-08-31 | 2021-01-29 | 微创神通医疗科技(上海)有限公司 | Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system |
CN111956275A (en) * | 2020-09-14 | 2020-11-20 | 聚辉医疗科技(深圳)有限公司 | Plugging device |
CN113081312B (en) * | 2021-03-29 | 2022-04-15 | 四川大学 | Developing wire and plugging device with developing function |
-
2021
- 2021-03-29 CN CN202110335915.8A patent/CN113081312B/en active Active
-
2022
- 2022-01-25 WO PCT/CN2022/073717 patent/WO2022206148A1/en active Application Filing
- 2022-03-07 NL NL2031176A patent/NL2031176B1/en active
Also Published As
Publication number | Publication date |
---|---|
CN113081312B (en) | 2022-04-15 |
NL2031176B1 (en) | 2024-05-06 |
WO2022206148A1 (en) | 2022-10-06 |
CN113081312A (en) | 2021-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL2031176B1 (en) | Radiopaque wire and occluder device with radiopaque function | |
JP4885866B2 (en) | Fillable polyphosphazene-containing particles for therapeutic and / or diagnostic applications and methods for their preparation and use | |
CA2596283C (en) | Embolization using poly-4-hydroxybutyrate particles | |
CA2410387C (en) | Polymerizable compositions and methods of use | |
EP1206287B1 (en) | High viscosity embolizing compositions | |
JP3356447B2 (en) | Vascular lesion embolic material composed of dried polymer gel | |
EP3348205A1 (en) | Absorbable occluder | |
JP5775912B2 (en) | Color-coded, size-sorted, fillable polymer particles for therapeutic and / or diagnostic applications, and methods for preparing and using them | |
EP2480166B1 (en) | Injectable hydrogel filaments for biomedical uses | |
US20130131716A1 (en) | Embolization device constructed from expansile polymer | |
JP2000506514A (en) | Vascular embolization | |
US9750506B2 (en) | Occluding device for occlusion of a body vessel and method for making the same | |
JP2007520275A (en) | Medical devices visible under magnetic resonance images | |
AU2019270949B2 (en) | Embolic compositions and methods | |
JP2021192838A (en) | Lubricant coating for medical device | |
US9107850B2 (en) | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same | |
CN115025294A (en) | Endothelialization promoting surface modification method of degradable occluder and modified degradable occluder prepared by method | |
US20060263301A1 (en) | In situ gelling self-reactive materials for embolization | |
KR101058196B1 (en) | Chitosan microspheres for embolization and preparation method thereof | |
WO2024217540A1 (en) | Microrobotic platform for endovascular embolization | |
CA2318546A1 (en) | Gynecologic endovascular embolotherapy methods | |
CN117159049A (en) | Fully degradable oval hole plugging device | |
CA2244418C (en) | Methods for embolizing blood vessels |